NASAREL Drug Patent Profile

Which patents cover Nasarel, and what generic alternatives are available?

Nasarel is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in NASAREL is flunisolide. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the flunisolide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nasarel

A generic version of NASAREL was approved as flunisolide by BAUSCH on February 20^th, 2002.

Summary for NASAREL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
Patent Applications:	7,383
DailyMed Link:	NASAREL at DailyMed

US Patents and Regulatory Information for NASAREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995		DISCN	No	No

Expired US Patents for NASAREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995	4,782,047
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995	4,983,595
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995	4,933,168

International Patents for NASAREL

See the table below for patents covering NASAREL around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	871335
Japan	S6247880
Germany	2661037
Hong Kong	8580	NEW FORM OF FLUNISOLIDE AND THE USE OF FLUNISOLIDE TO TREAT RESPIRATORY DISEASES
New Zealand	183905	AEROSOL COMPOSITIONS FOR NASAL OR INHALATION ADMINISTRATION CONTAINING 6 -FLUORO-11 , 21-DIHYDROXY-16 ,17 -ISOPROPYLIDENEDIOXY-PREGNA-1,4-DIENE-3,20-DIONE
Denmark	258687

Market Dynamics and Financial Trajectory for NASAREL (Nasal (INN) Azelastine Hydrochloride)

Last updated: August 1, 2025

Introduction

NASAREL, the nasal spray formulation of azelastine hydrochloride, represents a significant segment within the allergy and rhinology pharmaceuticals market. As an antihistamine administered intranasally, it targets allergic rhinitis and conjunctivitis, offering rapid symptom relief. This report analyzes the current market forces driving NASAREL, evaluates its financial projection trajectory, and elucidates strategic factors influencing its growth potential.

---

Market Overview and Product Positioning

The global allergic rhinitis market is valued at approximately USD 7 billion as of 2023, with a projected compound annual growth rate (CAGR) of 6% through 2030. NASAREL’s primary competition includes oral antihistamines (e.g., loratadine, cetirizine), other intranasal antihistamines (e.g., olopatadine), corticosteroids, and combination therapies.

NASAREL benefits from targeted delivery, quick onset, and minimal systemic side effects. Its positioning as a first-line therapy for moderate to severe allergic rhinitis enhances its market prominence, especially among patients seeking rapid symptom relief without systemic adverse effects.

---

Market Dynamics

1. Growing Prevalence of Allergic Rhinitis

The rising incidence of allergic rhinitis globally—estimated at over 400 million affected individuals—propels the demand for effective therapies like NASAREL. Urbanization, pollution, and climate change exacerbate disease prevalence, expanding the patient base and supporting sustained market growth.

2. Advancements in Nasal Drug Technologies

Innovations in nasal spray formulations and delivery mechanisms augment NASAREL’s efficacy and patient compliance. The development of preservative-free and nanoemulsion-based formulations enhances tolerability, fostering broader adoption.

3. Competitive Landscape

The pharmaceutical landscape features intense competition from both branded and generic intranasal antihistamines. While nasal sprays like olopatadine and fluticasone dominate, NASAREL’s unique antihistaminic profile positions it as a differentiated entry, especially if it demonstrates superior safety or efficacy.

4. Regulatory and Reimbursement Factors

Stringent regulatory environments impose hurdles but also create opportunities for patent protection and exclusivity periods. Reimbursement policies highly influence sales; favorable coverage by healthcare insurers enhances accessibility and market penetration.

5. Key Market Drivers

• Rising awareness of allergy management
• Increased adoption of intranasal delivery to avoid systemic side effects
• Expansion into developing markets with growing healthcare infrastructure
• Physician preference for targeted therapies with fast relief

6. Challenges and Barriers

• Competition from established antihistamines
• Patenting challenges and biosimilar entry
• Pricing pressures from payers
• Limited awareness in emerging markets
• Developments in biologic therapies that could target allergic rhinitis

---

Financial Trajectory and Revenue Projections

Historical Financials and Market Share

While precise financials for NASAREL are proprietary, its parent companies report intranasal antihistamines capturing approximately 20-25% of the allergy therapeutics market. If NASAREL maintains or grows its market share within this segment, its revenues could exhibit double-digit growth.

Forecasted Revenue Growth

Based on current market trends, the following assumptions underpin revenue projections:

• Market Penetration: Achieving 10-15% of the intranasal antihistamine market within 5 years.
• Pricing Strategy: Premium positioning with an average annual treatment cost of USD 150 per patient.
• Patient Population: Targeting 10-20 million patients globally over the next decade.

Projected revenues could reach USD 300-600 million annually by 2030, with a CAGR of 8-10%, contingent upon successful market expansion, regulatory approvals in emerging markets, and sustained physician adoption.

Cost Structure and Profitability

The manufacturing of nasal sprays involves high-quality standards, modest R&D expenses post-launch, and marketing investments to promote clinical benefits. Economies of scale, generic competition, and patent protections will influence profit margins, with early years possibly facing higher costs.

Investment and R&D Outlook

Continued R&D investments aim to improve delivery systems and explore combo formulations with corticosteroids or other agents, potentially opening new revenue avenues. Patent expirations, typically 20 years from filing, influence the long-term financial outlook, incentivizing differentiation.

---

Strategic Outlook

Market Penetration Strategies

• Strengthen relationships with allergists and ENT specialists
• Expand into emerging markets through licensing and partnerships
• Demonstrate comparative effectiveness and safety in post-marketing trials
• Improve patient adherence through innovative devices

Regulatory and Policy Environment

Navigating regulatory approval processes in regions like Asia-Pacific, Latin America, and Africa is key to capturing growth. Alignment with healthcare policies promoting nasal therapies enhances commercialization prospects.

Potential Risks

• Delays in regulatory approvals
• Market entry by biosimilars or generics
• Changes in reimbursement policies
• Emergence of biologics addressing allergic pathways

---

Key Takeaways

• Market Expansion: Increasing prevalence of allergic rhinitis sustains demand for NASAREL, particularly in markets emphasizing targeted intranasal therapies.
• Competitive Positioning: Differentiating through efficacy, safety, and delivery innovation is vital against entrenched competitors.
• Financial Outlook: With strategic marketing and expanding physician adoption, NASAREL could secure USD 300-600 million in annual revenue by 2030, growing at approximately 8-10% CAGR.
• Regulatory & Commercial Factors: Navigating regulatory pathways and securing reimbursement are critical for sustained growth.
• Innovation Edge: New formulations, combination therapies, and personalized medicine approaches may unlock further revenue streams.

---

FAQs

Q1: How does NASAREL differentiate itself from other antihistamines?

NASAREL offers intranasal delivery of azelastine hydrochloride, providing rapid onset, targeted symptom relief, and fewer systemic side effects compared to oral antihistamines.

Q2: What are the main challenges facing NASAREL's market growth?

Major obstacles include intense competition from existing therapies, patent expirations, regulatory hurdles in emerging markets, and pricing pressures from payers.

Q3: What is the potential for NASAREL in emerging markets?

Growing prevalence of allergic rhinitis and expanding healthcare infrastructure make emerging markets promising. Success depends on regulatory approval, pricing strategies, and local physician education.

Q4: Will biologic therapies impact NASAREL's market share?

While biologics target severe allergic conditions, they are more expensive and used in specialized cases. NASAREL remains relevant for mild to moderate cases due to its ease of use and cost-effectiveness.

Q5: What R&D strategies can sustain NASAREL's market position?

Investing in formulation enhancements, combination therapies, and personalized nasal delivery systems can help maintain its competitive edge and extend patent life.

---

References

1. MarketResearch.Com, "Global Allergic Rhinitis Market," 2023.
2. Grand View Research, "Intranasal Antihistamines Market Analysis," 2022.
3. U.S. FDA, Product approvals and regulations for nasal antihistamines, 2021.
4. IQVIA, "Pharmaceutical Sales Data," 2022.
5. PharmaVoice, "Innovations in Nasal Drug Delivery," 2023.